Introduction
Glioblastoma multiforme (GBM) is a uniformly fatal primary brain tumor that is classified by the World Health Organization as the most malignant astrocytoma (WHO Grade IV). In the United States, the rate of GBM occurrence is approximately 3.2 in 100,000 per year, making glioblastoma the most common primary brain tumor in adults. 1 With maximal surgical and medical treatment, the survival at 1 y of diagnosis is approximately 43% 2 and median survival is currently 15 months from the time of diagnosis. 3 Analysis of survival data from the SEER database between [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] demonstrates that the 5 y survival for Glioblastoma is approximately 20% for patients of ages up to 39 yrs, while that for patients aged 40-65 is approximately 5%. 1, 4 Despite strong efforts through research to find effective treatments for glioblastoma, these 5 y survival rates are only slightly improved compared to those from 1980-1989. 1 The current paradigm for GBM treatment was established in 2005, when a trial conducted by the European Organization for Research and Treatment of Cancer Brain Tumor and the National Cancer Institute of Canada Clinical Trials Group showed that treating patients with temozolomide, an oral alkylating agent, in addition to standard radiotherapy after surgical resection produced a 37% relative reduction in the risk of death. 4 Prior to this trial, the standard treatment for patients with glioblastoma consisted of surgical resection followed by targeted radiotherapy, with the median survival of approximately 12 months. Addition of temozolomide to the treatment protocol conferred a 2.5 month prolonged survival. Analysis of the SEER database reflects this result as the median survival of patients diagnosed in [2005] [2006] increased to 15 months from 12 months for those diagnosed in 2000-2001. 3 Subsequent trials evaluated the use of bevacizumab, a monoclonal antibody targeted against VEGF in relapsed GBM patients who have failed temozolomide and radiotherapy. The first studies in recurrent patients combined bevacizumab with irinotecan. 5 Irinotecan, a topoisomerase inhibitor, was implemented on account of its action through a mechanism separate from that of temozolomide. Bevacizumab was chosen as a potential therapeutic agent as it had been found to augment chemotherapy for lung, breast and colorectal cancers,. [6] [7] [8] The use of bevacizumab alone or in combination with CPT-11 (irinotecan, Camptosar) yielded similar overall survival (OS) times of 9 months. 9 In 2 different studies, the use of bevacizumab has been associated with improved clinical performance and a superior 6-month progression-free survival (PFS-6) of 42-50%. 5, 9 The significant objective response and favorable PFS seen in this phase II study resulted in US. Food and Drug Administration accelerated approval of bevacizumab for the treatment of recurrent GBM patients in 2009. As a next step, bevacizumab was tried in new-diagnosed GBM patients. Lai et al. used bevacizumab with temozolomide during and after radiation therapy for newly diagnosed GBM, and this group found the overall survival (OS) to be 19.6 months with this regimen, which is longer compared to the result of the EORTC-NCIC study (15 months) . 10 Interestingly, this OS was shorter in comparison to that of a cohort of patients treated at the same institution with temozolomide and radiation only (21.1 months). 10 Vrendenburgh et al studied standard therapy followed by bevacizumab, temozolomide and irinotecan for newly diagnosed GBM. 11 This study found the OS survival with this regimen to be 21.2 months, however 23% of participants terminated the study prematurely due to toxicity. 11 Thought the role of bevacizumab as first-line therapy remains controversial, recent analysis of the SEER database has revealed an increase in the 1-year survival from 41% to 43% and a significant decrease in the odds of death with the adoption of bevacizumab. 2 
Immunotherapy for Glioblastoma
Although the therapeutic advances mentioned above represent significant steps toward control of glioblastoma, in the past 20 years, the median survival has been lengthened by a mere few months. For this reason, many researchers have looked to other potential means besides radiation and chemotherapy for fighting this disease process. One of the major challenges in this process has been the selective targeting cancer cells without harming surrounding neurons, which are fully differentiated and incapable of regeneration. Immunotherapy has thus become vigorously pursued as a therapeutic modality that could potentially accomplish this goal. 12 Unfortunately, there are a number of obstacles that must be overcome to implement immunotherapy in the central nervous system (CNS), which is an immunologically privileged site in the body. 12 The CNS has a relative lack of lymphatic drainage and endogenous antigen-presenting cells (APCs) compared to the rest of the body. 12 Dendritic cells are virtually absent in the CNS, and expression of MHC class II molecules is limited to microglia, which are not as effective as antigen presenting cells. 12 Additionally, the CNS is isolated by blood brain barrier (BBB), which limits the movement of inflammatory cells and mediators. 12 The immunologic privilege that these features instill has been demonstrated in experiments that describe a delayed rejection of xenogenic tumor implants introduced into CNS parenchyma and slow clearance of virus inoculated into brain parenchyma. 13 Nevertheless, immune responses are able to occur in the CNS, albeit within the confines of its unique anatomy.
Immune surveillance of the CNS takes place under normal physiologic conditions and is predominantly carried out by memory T lymphocytes.
14 Immunohistochemical and immunofluorescent studies in mice models have demonstrated that fluorescent-labeled lymphocytes injected into the blood stream can be found in the choroid plexus stroma and meninges a couple hours following the injection. 15 Leukocytes may enter the CNS through the choroid plexus, through postcapillary venules and Virchow-Robin spaces into the subarachnoid space, and in the case of activated T cells, directly cross the blood brain barrier. 14 Inflammatory responses are able to occur in the CNS, but they occur more slowly than in other tissues. Injection of 20 ng of lipopolysaccharide (LPS) into a mouse's ear has been shown to produce a robust immune response within hours, while injection of 2 mg of LPS into the mouse hippocampus will draw a few polymorphonuclear cells into the brain parenchyma, followed by dramatic increase in the number of monocytes and microglia at 3 d. 16 Although the blood BBB significantly limits the passage of Abs and cells into the CNS, humoral immunity can also play a role in some CNS immune responses. 17 Inflammatory states, such as viral and autoimmune encephalitis, in which the BBB becomes "leaky," may allow for the passage of Ab and Ab-secreting cells into the CNS. Viral infection of the CNS has been shown to elicit the migration of Ab-secreting cells from lymphoid tissues into the CNS, 18 and intrathecal Ab secretion plays an important role in controlling viral replication following the initial infection. 19 Adding to the immunologically privileged status of the CNS is the relatively immunosuppressed state that is induced in the presence of glioblastoma. For decades, a reduction of T cell activity has been observed and recognized in patients with primary brain tumors, and this feature poses an additional challenge for enacting immunotherapy for glioblastoma. Decreased cell-mediated immunity, 20 impaired delayed-type hypersensitivity reactions, 21 decreased proliferative potential of T lymphocytes, 22 and release of substances that inhibit inflammatory mediators 23 have all been described in patients with primary brain tumors, including glioblastoma (see Fig. 1 ).
Mechanisms of immune suppression in glioblastoma may include secretion of immunosuppressive chemokines, such as transforming growth factor b (TGF-B), IL-10, and PGE2 23, 24 as well as recruitment of regulatory T cells (Treg cells) into tumor tissue. An increased proportion of Treg cells has been found in the tumors of glioblastoma patients, and they have been shown to impair T cell proliferation and reduce TH2 cytokines. 25, 26 This increased Treg cell activity is believed to contribute greatly to the immune suppression observed in glioblastoma. Treg cells suppress CD4 function by inhibiting the production of IL-2, which is a co-stimulator required for CD4 T cell activation. 27 Fecci et al. demonstrated that in a mouse model of glioblastoma, inoculation with an anti CD25 monoclonal Ab directed at Treg cells is capable of allowing for tumor rejection in 50% of mice, and in 100% of mice when administered along with an www.landesbioscience.com 3323 Human Vaccines & Immunotherapeutics anti-tumor dendritic cell vaccine. 25 This suggests that the inhibition of Treg cells could effectively restore cell-mediated immunity in patients with glioblastoma. 25 Tumor cells may induce immune suppression by promoting the recruitment and proliferation of Treg cells. 25, 28 This is suggested by in vitro studies in which glioblastoma stem cells isolated from human tumors were found to induce Treg cells, inhibit T cell proliferation and activation, and induce T cell apoptosis. 28 
EGFR as a Potential Target
Considering the effects of glioblastoma on the immune system, one would anticipate that immunotherapy would be most successful in young patients with healthy immune systems and in those who received gross total resection of their tumors. Additionally, a target for a vaccine therapy would need to be an antigen that could elicit a sufficiently strong immune response. To best accomplish this, the target should be an antigen that is expressed by the tumor and not by normal cells so that it would be perceived by the immune system as "foreign." Tumor antigens may arise from normal gene products that are over-expressed by tumor cells or mutated gene products that are not expressed in normal cells, and such antigens may serve as targets for immunebased therapies. For example, melanoma tumor cells express unique gene products, such as the GAGE gene family, which are not found in normal cells. 29 In a murine model of melanoma, these tumor-specific antigens were able to be recognized as foreign by cytotoxic T lymphocytes and elicit an immune response. 30 Similarly, a mutant, constitutively active epidermal growth factor receptor (EGFR) has been identified in some glioblastoma tumors, and has been extensively investigated as a tumor-specific antigen. Amplified EGFR occurs in approximately 50% of cases of GBM and mutated EGFR is found in about 30% of cases. 31 Mutated EGFR is expressed in multiple human tumors, including breast, ovarian and glial tumors, and plays an important role in tumorigenicity. 32 EGFR is a 170-kDa transmembrane glycoprotein receptor, which when stimulated by epidermal growth factor (EGF) acts as a tyrosine kinase, initiating a cascade of events resulting in gene transcription. 33 Multiple tumor types, including GBM, express a mutated form of the EGFR, which is constitutively active and enhances tumorigenicity by activating the Ras-Shc-Grb2 pathway. 34 The most common mutant form of EGFR in GBM is the EGFR class III variant (EGFRvIII), which has a truncated extracellular domain due to an 801 base pair in-frame deletion of the wild-type receptor. 35 This deletion results in the fusion of the 2 ends of the peptide and creation of an antigenic site which contains a novel glycine residue not included in the wild-type peptide. 36 Therefore the EGFRvIII serves as an ideal tumor-specific antigen for GBM. EGFRvIII is expressed in approximately 30% of GBMs, 31 and is found to be expressed on 37-86% of cells in a given tissue sample. 37 There is evidence that EGFRvIII may be "shared" among neighboring tumor cells by means of transfer via membrane-derived microvesicles, which may lead to the activation of oncogenic signaling pathways in recipient cells. 38 GBMs that express EGFRvIII are usually primary GBMs in which amplification or mutation of EGRF plays a central role in the pathway of tumor development. 39 Expression of EGRFvIII has been found to augment proliferation and inhibit apoptosis, [40] [41] [42] promote tumor cell motility, 43 and confer resistance to radiation and chemotherapy. [44] [45] [46] Interestingly, clinical and biochemical characteristics associated with poor prognosis in EGFRvIII-negative GBMs do not predict outcome in EGFRvIII-positive GBM. 47 Among GBM patients who have undergone gross total resection of their tumors and survived beyond 1 y of diagnosis, expression of EGFRvIII has been found to be an independent negative prognostic indicator. 31 
Preclinical Results of EGFRvIII Immunologic Targeting
Rindopepimut, or CDX-110, is a 14 amino acid peptide that has been implemented in raising an immune response against EGFRvIII. This synthetic peptide, also known as PEPvIII, corresponds to the fusion junction of EGFRvIII, which includes residues 1-5, the novel glycine residue, and residues 274-280 with a terminal cysteine. 48 To enhance its immunogenicity, the peptide is conjugated to the carrier protein keyhole limpet hemocyanin (KLH). PEPvIII has been shown to be capable of eliciting immune responses in in vivo models, and antibodies produced from vaccination with PEPvIII, have been shown to bind tumor cells expressing EGFRvIII. 48 In early in vivo studies, PEPvIII was shown to induce antibody (Ab) production in mice, rabbits, goats and Macaques. 48 In these experiments, the antisera produced from vaccination of the rabbits and one goat with PEPvIII alone was shown to exhibit specific binding to EGFRvIII on the surface of human glioma cells. In mice, immunization with PEPvIII needed to be combined with immunization with EGFRvIII to produce an efficient response. 48 Subsequently, high affinity mouse monoclonal Abs (mAbs) were able to be created using long term immunization protocols involving PEPvIII, and these mAbs were shown to be selectively reactive with EGFRvIII on the surface of breast cancer, non-small cell lung cancer, and glioma cells. 37 One of these antibodies, Y10, which is of the IgG2a class, was shown to inhibit DNA synthesis, impair cellular proliferation and induce antibody-dependent cell-mediated toxicity in vitro. 49 Mice that were pretreated with injections of Y10 and then inoculated with melanoma tumor cells never developed palpable tumors unlike their control counterparts. In mice with established intracranial melanoma tumors, systemic injections with Y10 failed to increase survival, however, a single intratumoral injection of Y10 was found to increase median survival by 286% on average. 49 These data provided compelling support that immunotherapies such as vaccination and tumor-directed Abs could effectively treat malignancies of the central nervous system.
Another mAb directed against EGFRvIII, mAb 806, was produced by immunizing mice with mouse fibroblasts expressing EGFRvIII. MAb 806 was shown to inhibit the growth of developing and established EGFRvIII-positive human glioma xenografts in mice in a dose-dependent manner. 50 Interestingly, mAb 806 was also shown to inhibit the growth of xenografts which overexpressed wild-type EGFR 50-52 and to reduce phosphorylation of EGFR and increase apoptosis of these tumor cells. 51 mAb 806 did not bind cells that expressed normal levels of EGFR, and was found to recognize about 10% of the total number of receptors present on cells overexpressing EGFR. 53 These findings suggested that certain EGFR-directed antibodies may be used to target EGFRvIII-expressing and EGFR-overexpressing tumor cells without binding to other tissues that naturally express EGFR, such as liver and skin.
Vaccination against EGFR-vIII was also proven to be efficacious in murine models of intracerebral tumors. PEPvIII conjugated to keyhole limpet hemocyanin (PEPvIII-KLH) was effectively used to vaccinate mice against EGFR-vIII, rendering them capable of developing immune responses against developed EGFR-vIII-positive melanoma tumors. 54 Heimberger et al showed that 70% mice vaccinated with PEPvIII-KLH failed to develop subcutaneous EGFR-vIII-positive melanoma tumors when challenged with subcutaneous injection of tumor cells, and those that did develop tumors had significantly smaller tumors compared to controls. 54 The response that the mice developed as a result of vaccination was found to be humoral in nature and to be dependent on CD8C Cytotoxic T lymphocytes (CTLs) and natural killer cells. 54 In a mouse strain in which peptides spanning the splicing site of EGFRvIII were predicted to bind strongly to MHC class I, vaccination with PEPvIII-KLH prior to an intracerebral tumor challenge was found to increase median survival > 173% compared to controls. 54 Furthermore, a onetime vaccination of mice having established intracerebral tumors was shown to increase the median survival by 26% with 40% of the mice having long-term survival. 54 Subcutaneous tumors that recurred were tested with immunohistochemistry, and interestingly, 80% of relapsing tumors were found to have lost EGFR expression.
54
To boost the cell-mediated immune response against EGFRvIII-expressing tumors, dendritic cells were later implemented in the vaccination paradigm. 55 Dendritic cells are potent antigenpresenting cells that express high levels of MHC class II molecules for effectively presenting antigens to and activating naive T cells. 55 Vaccination with dendritic cells pulsed with glioma peptides had previously shown to prolong survival of rats having intracranial gliomas. 56 In experiments conducted by Heimberger et al., mice that received a vaccine of dendritic cells mixed with PEPvIII-KLH and then administered a lethal intracerebral injection of EGFRvIII -expressing melanoma cells exhibited a 600% increase in median survival with 5 of 8 mice surviving longterm. 57 Those mice that survived the lethal tumor challenge were then re-challenged with an intracerebral injection of tumor cells into the contralateral hemisphere, and all immunized mice survived. 57 This experiment demonstrated that vaccination with dendritic cells mixed with PEPvIII-KLH could induce lasting immunity. 57 As vaccination with PEPvIII-KLH had previously been shown to be weakly effective in a mice of the C57BL/6J background, 54 which was believed to be due to poor binding to MHC class I molecules, experiments with the dendritic cell vaccine were designed to identify an epitope in the EGFRvIII peptide that would most strongly bind HLA-A0201 on U87 glioma cells. 58 Peptides were created based on analyses of software that could predict the binding affinities of certain peptide sequences spanning the splice site of the EGFRvIII protein to a specific HLA class I molecule on U87 glioma cells. 58 Three peptides were created and 3 dendritic cell vaccines were produced with these peptides and used to stimulate CTLs, with one peptide eliciting a significantly higher response than the other 2. CTLs that were stimulated with this peptide were shown to effectively lyse tumor cells, while the CTLs stimulated by the other 2 peptides did not. 58 These findings demonstrate that that the HLA haplotype expressed by glioma cells may affect CTL responses to dendritic cell tumor vaccines. 58 The findings of these experiments support that both humoral responses, such as Ab production, and cytotoxic immune responses, such as the generation of tumor-specific cytotoxic T cells, may be useful for glioblastoma immunotherapy (Fig. 2) . However, the presence of the BBB may create an additional barrier for Ab-based immunotherapies, and methods of enabling CNS penetration may be needed for such therapies to be effective. Immunotherapies which lead to the generation of tumor-directed cytotoxic T cells may be particularly useful for glioblastoma because activated T cells can cross the BBB and lyse tumor cells. Furthermore, these experiments demonstrate the importance of HLA haplotype to the efficacy of EGRFvIII vaccination. The affinity with which MHC class I proteins bind to PEPvIII determines the strength of the immune response that is produced. Heimberger 54 Based on the frequencies of human haplotypes that are predicted to bind strongly to PEPvIII, this group calculated that the chance that a glioma patient would be able to elicit a strong response to PEPvIII vaccination is about 64%.

Clinical Results of EGFRvIII Vaccination
The first clinical trial investigating the use of PEPvIII-KLH for vaccination of human subjects with glioblastoma implemented the dendritic cell mediated approach, in which mature dendritic cells were pulsed with Pep3-KLH. The VICTORI trial was a phase I trial conducted at Duke University Medical Center, which enrolled 15 newly diagnosed GBM patients who had gross total resection of their tumors and underwent standard external beam radiation therapy. 59 Given that this study was designed primarily to assess toxicity, patients were not pre-screened for EGFRvIII-expression. 59 The 12 patients out of 15 who did not have progression during radiation therapy received 3 vaccinations of an autologous dendritic cell vaccine with each vaccination spaced 2 weeks apart. 59 Toxicity from the vaccine was minimal, and patients did not develop any symptoms of autoimmunity. To assess the cellular immune response to vaccination, patients underwent delayed-type hypersensitivity (DTH) testing with Pep3 and KLH before and after vaccination. 59 None of the patients had a response to KLH or PEPvIII before vaccination, but 9 of 9 who were tested showed a positive response to KLH after vaccination and 5 of 9 showed a positive response to Pep3. The median time to progression after vaccination was found to be 6.8 months, and the proportion of patients without disease progression at 6 months was 0.67 and at 12 months was 0.33. 59 The median survival after diagnosis was 22.8 months and 18.7 months after vaccination. 59 Curran's recursive partition analysis was used to determine if the patients had better outcomes than would be expected by chance, and while 9 out of 12 patients had better than expected outcomes, this result did not reach statistical significance. 59 The ACTIVATE (A Complementary Trial of an Immunotherapy Vaccine against Tumor Specific EGRFvIII) trial was the first phase II study to evaluate the efficacy and safety of PEPvIII-KLH as a vaccine therapy for GBM. 60 Due to the variability and high cost associated with the autologous dendritic cell vaccine, patients enrolled in the ACTIVATE and subsequent trials were vaccinated with PEPvIII-KLH and GM-CSF alone. 60 Eighteen patients with newly diagnosed GBM who were screened for EGFRvIII expression were enrolled at MD Anderson Cancer Center and Duke University Medical Center. 60 Each patient received gross total resection of their tumor, underwent external beam radiation therapy and concurrent temozolomide (TMZ) with no radiographic progression, and had a Karnofsky performance status (KPS) of > or D to 80. Patients were vaccinated 3 times at 2 week intervals and then every month until progression occurred. 60 The outcome of the treatment group compared favorably with a control group that received the standard surgical resection with radiation therapy and TMZ with a median time to progression (TTP) of 14.2 months and a median overall survival (OS) of 26.0 months (hazard ratio: 5.1; 95% CI: 1.9-13.9, P D 0.001). 60 Six of the 14 patients who had their serum tested were found to have antibodies specific for PEPvIII, and the median OS of these patients was found to be significantly higher compared to the OS of those who did not develop a humoral response (47.7 months vs. 22.8 months, P D 0.025). Patients who developed a cellular immune response to PEPvIII (3 out of 17 patients) also demonstrated significantly longer PFS and OS (P D 0.03) with median OS from time of histologic diagnosis being unreached after 50 months of follow up compared to 23.1 months for those that did not develop cellular immune responses. 60 In cases of recurrent GBM, most tumors were found to have lost EGFRvIII expression. 60 Another phase II trial, entitled ACT II, was constructed to determine if TMZ-induced lymphopenia would enhance immune responses to the PEPvIII-KLH vaccine. 61 This hypothesis was based on results from experiments in animals and humans that suggested that lymphopenia may support anti-tumor immunity by eliminating the effect of Treg cells and homeostatic mechanisms inducing T cell tolerance. 62, 63 This study enrolled 22 patients with newly diagnosed EGFRvIII-positive GBM. 61 All patients underwent gross total resection of their tumors followed by standard radiation therapy with TMZ and were subsequently screened for progression. 60 Twelve patients were then assigned to receive TMZ at a targeted dose of 200 mg/m 2 for the first 5 d of a 28-day cycle (standard dose) and the remaining 10 patients were assigned to receive a targeted dose of 100 mg/m 2 for the first 21 d of a 28 day cycle (intensified dose). 61 Vaccinations with PEPvIII-KLH with GM-CSF were initiated within 6 weeks of completing radiation therapy. 57 The first 3 vaccinations were given at 2 week intervals and subsequent vaccinations were administered monthly until progression. Four patients in the group receiving the dose-intensified regimen of TMZ experienced possible allergic drug reactions, and one was removed for toxicity-related reasons while 2 others were removed for tumor progression. 61 The grade of lymphopenia was greater and sustained in the dose-intensified group compared to the standard dose TMZ group, however, the proportion of Treg cells was actually found to be higher in the dose-intensified group. All patients in the study developed antibody titers to PEPvIII, however those patients in the dose intensified group demonstrated increasing antibody titers over time such that their titers became higher than those of the standard dose group. 61 In addition, more patients in the dose intensified group developed DTH reactions to PEPvIII compared to the standard dose group. In the standard dose group, 9 out of 12 patients were progression free 6 months after vaccination, and 10 of 12 patients were alive at 12 months. 61 In the dose-intensified group, 9 of 10 patients were progression free 6 months after vaccination, and 9 of 10 patients were alive at 12 months. The median PFS from the time of histologic diagnosis for all patients was 15.2 months (95% CI: 11.0-18.5), and the OS for all patients was 23.6 months (95% CI: 18.5-33.1). This compared favorably with the PFS and OS of the historic control group (6.3 months [95% CI: 4.1-9.0] and 15.0 months [95% CI: 11.4-19.7], respectively. 61 After adjusting for KPS and age, there was no difference in OS between the 2 TMZ cohorts, although the study had not been powered to detect such a difference. 61 The ACT III trial was the third phase II trial to investigate the efficacy and safety of the Rindopepimut vaccine. 64 This study included 65 patients at 31 different centers with newly diagnosed primary, EGFRvIII-positive GBM who underwent gross total resection and did not show evidence of progression after radiation and TMZ therapy. 64 The treatment regimen consisted of 3 vaccinations with PAPvIII-KLH/GM-CSF at 2 week intervals and then vaccinations monthly until progression. 64 This vaccination regimen was accompanied by 150-200 mg/m 2 doses of TMZ administered for the first 5 d of a 28 day cycle, which was repeated until progression. 64 Almost all patients developed injection site reactions and 2 patients had to discontinue treatment because of toxicity.
64 85% of patients developed anti EGFRvIII antibody titers, which were observed to increase over the duration of the study. 64 The PFS and OS after histological diagnosis was found to be 12.3 months and 24.6 months, respectively, and the PSF at 8.5 months from diagnosis was 66%. 64 These survival lengths compare favorably to that of an EGFRvIII-positive control group who received the standard treatment of gross total resection and radiation therapy with concurrent TMZ (P D 0.00088 for PFS and P= < 0.0001 for OS) 64 . Additionally, patient outcomes were analyzed based on methylation status of MGMT, and those with methylated MGMT were found to have a significantly longer PFS (17.5 months vs 11.2 months, P D 0.0057) and OS (32.3 months vs 20.9 months, P D 0.0067). 64 These results support that the rindopepimut vaccine may be advantageous for augmenting standard therapy for GBM. 64 The rindopepimut vaccine has been shown to be generally well-tolerated and to lengthen PSF and OS in patients with both methylated MGMT, and unmethylated MGMT. 64 Due to the promising results of the previous phase II trials, multiple further studies of rindopepimut for GBM have been initiated. Current ongoing studies include a phase III trial investigating the efficacy of rindopepimut for newly diagnosed GBM (ACTIV). This study is planned to include 374 patients with newly diagnosed EGFR-positive GBM, and will be conducted internationally at over 150 different centers. ACT IV is a randomized, double-blind trial of rindopepimut vaccination compared to vaccination with KLH alone. The primary outcomes will be PFS, OS and quality of life. Patients with incomplete resection will be included so that the efficacy of rindopepimut on residual tumor burden may be assessed. The reACT trial is another phase II trial that evaluates the efficacy of the rindopepimut vaccine with concurrent bevacizumab in patients with EGFR-positive recurrent GBM. In this study, one subset of patients is randomized to receive vaccination with either rindopepimut or KLH, both in conjunction with bevacizumab therapy. The other subset, which will consist of patients who are refractory to bevacizumab, will receive vaccination with rindopepimut in conjunction with bevacizumab. Ninety-five patients are planned to be enrolled in this study, and the effect of residual tumor burden will be evaluated. As the previous ACT trials adhered to strict selection criteria favoring healthier patients with less disease burden, the results of the ReACT trial will more clearly demonstrate the efficacy of the vaccine in a study group which is more representative of the majority of patients living with glioblastoma. The ACT III and ReAct trials were expected to be completed in November 2016 and March 2014, respectively.
Road Blocks to EGFRvIII Targeting
EGFRvIII targeting is a very attractive strategy for developing immunotherapies for GBM as EGFRvIII is one of the few antigens that can be found exclusively on tumor cells and not on normal tissues. The rindopepimut vaccine has been successful in stimulating immune responses to EGFRvIII in GBM patients as it incorporates a unique epitope including a novel glycine not present in the wild-type peptide, which contributes to its immunogenicity. 49, [59] [60] [61] 64 Although rindopepimut has been shown to prolong survival of patients with glioblastoma, limitations of this modality have been encountered in clinical trials. [59] [60] [61] 64 First, EGFRvIII targeting is useful in only a subset of GBM patients, which comprises about 20-40% of the total number of cases. Therefore, patients must be screened for EGFRvIII before they can be considered for vaccination. Additionally, in all 3 completed clinical trials (ACTIVATE, ACT II, and ACT III), recurrent GBMs were found to have lost EGFR expression, indicating that the tumor is able to escape through the selection and proliferation of cells that are EGFR negative. [59] [60] [61] 64 Therefore, the rindopepimut vaccine may lose its value in treatment once the GBM recurs. Other alternative therapies would then need to be implemented for continued control of tumor growth. [59] [60] [61] 64 One strategy that attempts to overcome this obstacle is vaccination against multiple tumor antigens simultaneously. The aim of this approach is to decrease the ability of the tumor to escape www.landesbioscience.com 3327 Human Vaccines & Immunotherapeutics as each cell should be positive for at least one of the antigens included in the vaccine. [59] [60] [61] As these antigens may not be very antigenic themselves, dendritic cells could be also potentially used to present the antigens to T cells to stimulate an immune response. Several groups have used whole tumor lysates to vaccinate patients with GBM. 65 Prim et al. vaccinated a mixed group of newly diagnosed and recurrent GBM patients (n D 23) with a vaccine consisting of autologous dendritic cells pulsed with autologous tumor lysate obtained from tumor samples from surgical resection. 65 Although this Phase I study was not powered to evaluate clinical efficacy, the median PFS was found to be 15.9 months and the median OS was 31.4 months. Interestingly, 3 patients in this group survived over 6 y In this study, no serious adverse events or autoimmune reactions were observed. 65 Similarly, Wheeler et al. conducted a phase II clinical trial using an autologous dendritic cell vaccine to vaccinate 23 recurrent and 11 newly diagnosed GBM patients. 66 Seventeen patients exhibited a positive immune response after vaccination, as measured by levels of INF-g, while 14 showed no response, and the remaining 3 were not able to be tested. 66 Mean PSF was 308 C/¡ 55 d in responders and 167 C/¡ 22 d in non-responders while mean OS was 642 C/¡ 61 d in responders and 430 C/¡ 50 in non-responders. As expected, responders to the vaccine tended to be newly diagnosed patients. 66 These patients, similar to those in the rindopepimut trials, eventually experienced progression, and so it is obvious that escape from immunity must have occurred with this vaccine as well. 66 Attempting to vaccinate against multiple tumor antigens may not always provide complete protection as many tumor antigens may also be expressed on normal tissues and may not be immunogenic. 66 One of the benefits of using tumor lysates in vaccination is that patients do not require screening for a particular antigen and any tumor, regardless of molecular markers, may receive vaccine therapy. The disadvantage with this approach is that autologous dendritic cell vaccines are very costly to manufacture and they can only be manufactured on an individual basis. The inherent lack of efficiency with autologous dendritic cell vaccine production inevitably causes this therapy to appear less attractive to corporate sponsors, and lack of sponsorship impedes the production of expensive phase III trials required for FDA approval. 67 Efforts to maximize the efficacy of dendritic cell vaccines through promoting a robust cytotoxic T cell response have been initiated with the development of a-type 1 polarized dendritic cells. 68 The maturation process of dendritic cells in culture has been found to lead to decreased ability to produce IL-12, which is critical to inducing a cytotoxic-supporting Th 1 response. 69 When dendritic cells are matured in the presence of INF-gamma and tumor necrosis factor they have been demonstrated to produce significantly higher levels of IL-12, 68 and this maturation process has been associated with prolonged progression free survival in some patients with recurrent glioblastoma. 70, 71 Further studies would be needed to determine if the efficacy of Th 1 polarized dendritic cell vaccines could offset the inefficiency of dendritic cell vaccine production. Peptide vaccines may be mass-produced and are relatively inexpensive, and large, multi-center phase III clinical trials are more manageable. 67 Therefore, while PEPvIII-KLH vaccination may not be indicated for all GBM patients, this vaccine may be easily implemented as an efficacious adjuvant to standard therapy in a relatively large subset of patients. 59, 67 Peptide vaccines which aim to immunize GBM patients against multiple tumor peptides have been developed as well. Similar to rindopepimut, such vaccines consist simply of tumorderived peptides mixed with an immune adjuvant. For example, Ishikawa et al. treated 24 newly diagnosed GBM patients with a formalin-fixed vaccine made from autologous tumor lysates. 72 The median OS and PFS were 22.2 months and 8.2 months, respectively. 72 Of note, this group found that positive DTH responses of equal or greater than 10 mm of induration correlated with longer PFS durations, however this correlation did not reach statistical significance. 72 Terasaki et al. developed a vaccine for GBM patients comprised of a personalized combination of several synthetic tumor peptides. 73 The peptides were identified from a group of over 100 genes encoding proteins that are expressed at high levels in cancer cells and that play a role in cell proliferation. 73 Fourteen peptides were selected based on their ability to elicit peptide-specific immune responses in HLA-A24-positive patients with GBM or other cancers. 73 For the individual vaccines designed for each of the 12 patients with recurrent GBM included in a phase I trial, up to 4 peptides out of the 14 were selected based on those which elicited the strongest immune responses in each patient. 73 Although the trial was designed specifically to determine the safety and highest tolerated dose of vaccine, the PFS at 6 months was noted to be 16.7% and the OS survival was 10.6 months. 73 Compared to PEPvIII, the peptides included in these vaccines may not be as immunogenic because many of them may be expressed at low levels in normal cells. Nevertheless, with the aid of immune adjuvants, tumor-derived peptides may be capable of eliciting anti-tumor immune responses in certain patients.
As some peptide vaccines include a variety of tumor-specific antigens, PEPvIII might be combined with other tumor peptides to induce a cytotoxic response targeting multiple tumor antigens. This might help prevent the antigenic escape of tumor cells as observed with immunization against EGFRvIII alone. Another option may be to combine EGFRvIII vaccination with other adjuvant immunotherapies. One example is anti-programmed cell death-1 antibodies, which have shown some promising results in patients with widespread malignancies, including melanoma, colon cancer, and prostate cancer. 74 Programmed cell death-1 is an inhibitory co-stimulator located on the surface of activated T and B cells, and its expression may contribute to the immune resistance of tumors. 75 Inhibition of this co-stimulator has been shown to have anti-tumor effects in murine models of carcinomas, 75, 76 and if able to be effectively implemented for glioblastoma, this therapy could theoretically boost the cytotoxic response initiated by vaccination against EGFRvIII. Of course, use of antibody-based therapies for GBM may require direct inoculation into the CNS, as transfer across the blood-brain-barrier is highly inefficient.
In summary, rindopepimut is a peptide vaccine that has been shown to potentially prolong survival in EGFRvIII-positive GBM patients -pending the final confirmation in a large,
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Volume 10 Issue 11 Human Vaccines & Immunotherapeutics ongoing phase III clinical trial (ACTIV). This vaccine targets the EGFRvIII surface antigen, a mutated form of the EGFR receptor that is present only on tumor cells and not in normal healthy tissues. Due to the foreign nature of this peptide, vaccination is capable of eliciting significant anti-tumor immune responses. This immunotherapy has the potential to contribute to extended survival when used in conjunction with standard therapies, including surgical resection, radiation therapy and TMZ chemotherapy. In the future, tumor-directed vaccination may be incorporated into the standard therapeutic regimen for GBM, however, the timing of vaccination to best induce a clinically relevant anti-tumor immune response may require further investigation. Although GBMs may eventually escape EGFRvIII targeting through loss of expression of EGFRvIII, the rindopepimut vaccine may be efficacious as an initial therapy to augment radiation and chemotherapy in newly diagnosed EFGRvIII-positive GBM patients. As more discoveries are made regarding the pathophysiology of GBM and more targets for immunotherapies are discovered, future treatment of GBM will likely consist of combined modalities that are customized for unique genetic makeup of an individual's tumor.
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